Cognitive Phenotypes in Parkinson's Disease (CogPhenoPark)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01792843|
Recruitment Status : Completed
First Posted : February 15, 2013
Last Update Posted : February 2, 2017
- a data driven approach has identified different cognitive phenotypes in Parkinson's disease (PD)
- this heterogeneity possibly reflects the diversity of the neuronal damage caused by the disease
- we hypothesize that the different clinical presentations are associated to specific anatomical and functional correlates
|Condition or disease||Intervention/treatment|
|Parkinson Disease||Behavioral: data|
Cognitive impairments are frequent in PD, even in non-demented patients. However, there is a substantial heterogeneity in the clinical presentation of cognitive deficits in PD 2 and also in their progression. This heterogeneity possibly reflects the diversity of the neuronal damage caused by the disease and recent studies suggest that these different clinical influence the risk of developing dementia.
Most studies on cognitive phenotypes in PD have used predefined categories, such as demented vs. non-demented, or PD-mild cognitive impairment vs. cognitively intact patients. However, such an approach may miss less obvious or unexpected presentations. To this end, in a first part of this study, we have used a data-driven approach (cluster analysis) to identify different cognitive phenotypes in PD. With such an approach where phenotypical profiles arise from the data without a priori assumptions, five cognitive presentations were identified: i°) cognitively intact patients (19.39%), ii°) patients with slight mental slowing and mild executive dysfunction (41.29%), iii°) patients with slightly impaired overall cognitive efficiency and deficits in all cognitive domains except recognition memory (12.93%), iv°) patients with severe mental slowing, impaired overall cognitive efficiency, and severe cognitive impairment in all domains, including memory (23.88%), and v°) patients with very severe impairment in all cognitive domains (2.51%). From these results, it could be hypothesized that cognitive deterioration in PD progresses along a continuum, with the exception of the fourth group that also exhibits memory deficits. This group may be characterized by a different underlying pathology, or comorbidity with Alzheimer's disease. The role of vascular factors has also to be considered.
The objectives of the current project are:
- to validate the identified cognitive profiles prospectively in a new population using confirmatory cluster analysis.
- to identify specific anatomical correlates for the identified cognitive profiles by magnetic resonance-imaging (MRI) scanning
- to identify specific functional correlates of the identified cognitive profiles by high-density EEG (hd-EEG)
|Study Type :||Observational|
|Actual Enrollment :||158 participants|
|Official Title:||Cognitive Phenotypes in Parkinson's Disease: Anatomical and Functional Correlates|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||December 2014|
Patients with Parkinson's disease according to international criteria
- Frequency (%) of the cognitive profile [ Time Frame: 2 years ]Frequency of the different observed cognitive profile, as coming from the cluster analysis
- Grey matter density (voxels) [ Time Frame: 2 years ]Grey matter density as measured by voxel-based morphometry
- EEG power (microvolts2) [ Time Frame: 2 years ]EEG power in the different frequency bands
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01792843
|Maastricht University Medical Centre|
|Principal Investigator:||Kathy Dujardin, PhD||University Hospital, Lille|